2 results
Approved WMOPending
The objective of this study is to evaluate the dose-ranging response in safety and efficacy of R115866 0.5mg, 1mg and 2mg and R115866 placebo given once daily for the treatment of subjects with plaque psoriasis to select a dose for further clinical…
Approved WMOPending
Comparing the efficacy of encorafenib and cetuximab plus pembrolizumab (triplet group [group A]) vs. pembrolizumab (control group [group B]).Assessing the overall safety and tolerability of group A vs. group B.Assessing the efficacy of group A vs.…